These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31676272)

  • 1. Accelerated Aggregation Studies of Monoclonal Antibodies: Considerations for Storage Stability.
    Wälchli R; Vermeire PJ; Massant J; Arosio P
    J Pharm Sci; 2020 Jan; 109(1):595-602. PubMed ID: 31676272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions.
    Brummitt RK; Nesta DP; Roberts CJ
    J Pharm Sci; 2011 Oct; 100(10):4234-43. PubMed ID: 21671226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational implications of an inversed pH-dependent antibody aggregation.
    Perico N; Purtell J; Dillon TM; Ricci MS
    J Pharm Sci; 2009 Sep; 98(9):3031-42. PubMed ID: 18803243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Throughput Prediction Approach for Monoclonal Antibody Aggregation at High Concentration.
    Zidar M; Šušterič A; Ravnik M; Kuzman D
    Pharm Res; 2017 Sep; 34(9):1831-1839. PubMed ID: 28593474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An accelerated surface-mediated stress assay of antibody instability for developability studies.
    Kopp MRG; Wolf Pérez AM; Zucca MV; Capasso Palmiero U; Friedrichsen B; Lorenzen N; Arosio P
    MAbs; 2020; 12(1):1815995. PubMed ID: 32954930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of Colloidal and Conformational Stabilities to Aggregate Formation in a Monoclonal Antibody.
    Oyama H; Koga H; Tadokoro T; Maenaka K; Shiota A; Yokoyama M; Noda M; Torisu T; Uchiyama S
    J Pharm Sci; 2020 Jan; 109(1):308-315. PubMed ID: 31669120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage.
    Svilenov H; Winter G
    Eur J Pharm Biopharm; 2019 Apr; 137():131-139. PubMed ID: 30818009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of biophysical characterization techniques in predicting monoclonal antibody stability.
    Thiagarajan G; Semple A; James JK; Cheung JK; Shameem M
    MAbs; 2016; 8(6):1088-97. PubMed ID: 27210456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frozen state storage instability of a monoclonal antibody: aggregation as a consequence of trehalose crystallization and protein unfolding.
    Singh SK; Kolhe P; Mehta AP; Chico SC; Lary AL; Huang M
    Pharm Res; 2011 Apr; 28(4):873-85. PubMed ID: 21213025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thermodynamic Unfolding and Aggregation Fingerprints of Monoclonal Antibodies Using Thermal Profiling.
    Melien R; Garidel P; Hinderberger D; Blech M
    Pharm Res; 2020 Apr; 37(4):78. PubMed ID: 32236701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the Increased Aggregation Propensity of a Light-Exposed IgG1 Monoclonal Antibody Using Hydrogen Exchange Mass Spectrometry, Biophysical Characterization, and Structural Analysis.
    Bommana R; Chai Q; Schöneich C; Weiss WF; Majumdar R
    J Pharm Sci; 2018 Jun; 107(6):1498-1511. PubMed ID: 29408480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orthogonal Techniques to Study the Effect of pH, Sucrose, and Arginine Salts on Monoclonal Antibody Physical Stability and Aggregation During Long-Term Storage.
    Svilenov HL; Kulakova A; Zalar M; Golovanov AP; Harris P; Winter G
    J Pharm Sci; 2020 Jan; 109(1):584-594. PubMed ID: 31689429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of temperature and osmolytes on competing degradation routes for an IgG1 antibody.
    Roberts CJ; Nesta DP; Kim N
    J Pharm Sci; 2013 Oct; 102(10):3556-66. PubMed ID: 23873602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of High Throughput Screening Techniques to Predict Stability of Monoclonal Antibody Formulations During Early Stage Development.
    Goldberg DS; Lewus RA; Esfandiary R; Farkas DC; Mody N; Day KJ; Mallik P; Tracka MB; Sealey SK; Samra HS
    J Pharm Sci; 2017 Aug; 106(8):1971-1977. PubMed ID: 28456733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-order nucleation and subsequent growth promote liquid-liquid phase separation of a model IgG1 mAb.
    Tian Z; Xu L; Zhang N; Qian F
    Int J Pharm; 2020 Oct; 588():119681. PubMed ID: 32721563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of arginine glutamate on the stability of monoclonal antibodies in solution.
    Kheddo P; Tracka M; Armer J; Dearman RJ; Uddin S; van der Walle CF; Golovanov AP
    Int J Pharm; 2014 Oct; 473(1-2):126-33. PubMed ID: 24992318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations.
    Awotwe-Otoo D; Agarabi C; Read EK; Lute S; Brorson KA; Khan MA
    Int J Pharm; 2015 Jul; 490(1-2):341-50. PubMed ID: 25835267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates.
    Arosio P; Rima S; Morbidelli M
    Pharm Res; 2013 Mar; 30(3):641-54. PubMed ID: 23054090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the Aggregation Kinetics of a Therapeutic Antibody Fragment.
    Chakroun N; Hilton D; Ahmad SS; Platt GW; Dalby PA
    Mol Pharm; 2016 Feb; 13(2):307-19. PubMed ID: 26692229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced Subvisible Particle Formation in Lyophilized Intravenous Immunoglobulin Formulations Containing Polysorbate 20.
    Zhou C; Qi W; Lewis EN; Randolph TW; Carpenter JF
    J Pharm Sci; 2016 Aug; 105(8):2302-9. PubMed ID: 27290624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.